Pfizer and BioNTech Submit Data Backing Vaccine for Children 5 to 11
The companies said that their vaccine was safe and effective in that age group, and that they would submit a formal request in the coming weeks to U.S. regulators to allow a pediatric dose.
There are no comments yet.